Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants

Elisabeth Andersen, MSc, Maria Eugenia Chollet, Marcello Baroni, Mirko Pinotti, Francesco Bernardi, Ellen Skarpen, Per Morten Sandset, Grethe Skretting

Blood (2018) 132 (Supplement 1): 3777.

https://doi.org/10.1182/blood-2018-99-118246

Published: 2018

Journal Articles

The Impacts of Transcriptional Regulatory Mechanism and Protein Interaction Relationship between RUNX1 and KLF4 on the Biological Functions of t (8;21) Leukemia Cells

Shuang Liu, PhD, Wenting Lu, PhD, Shouyun Li, PhD, Saisai Li, PhD, Ying Wang, PhD, Jia Liu, MD, Zheng Tian, BS, Haiyan Xing, MS, Kejing Tang, BS, Yingxi Xu, PhD, Qing Rao, MS, Min Wang, MD, Jianxiang Wang, MD

Blood (2017) 130 (Supplement 1): 3802.

https://doi.org/10.1182/blood.V130.Suppl_1.3802.3802

Published: 2017

Journal Articles

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Hector Cordero-Nieves, BS, Douglas W. Sborov, MD, Alessandro Canella, MS, Zhongfa Liu, Jessica Consiglio, MS, Wenjun Ni, Emily Smith, Lara Rizzotto, PhD, Yvonne A Efebera, MD, Don M. Benson, MD PhD, Luciano Cascione, Mo Xiaokui, MS, John C. Byrd, MD, Michael R. Grever, MD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2014) 124 (21): 3377.

https://doi.org/10.1182/blood.V124.21.3377.3377

Published: 2014

Journal Articles

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Benjamin Esterni, Ph.D., Raphael Itzykson, Sylvain Thepot, C.L. Beach, PharmD, Pierre Fenaux, MD, PhD, Norbert Vey, MD

Blood (2010) 116 (21): 443.

https://doi.org/10.1182/blood.V116.21.443.443

Published: 2010

Journal Articles

Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).

Duane Hassane, PhD, Marlene Balys, Guido Marcucci, M.D., John C. Byrd, Craig T. Jordan, PhD, Monica L. Guzman, PhD

Blood (2009) 114 (22): 2070.

https://doi.org/10.1182/blood.V114.22.2070.2070

Published: 2009

Journal Articles

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Susan Perrine, MD, William C Welch, PhD, Jeffrey Keefer, MD, PhD, Robin L Downey, MD, Michael S Boosalis, PhD, Sally Case, RN, Douglas V Faller, MD, PhD, Ronald Berenson, MD

Blood (2008) 112 (11): 130.

https://doi.org/10.1182/blood.V112.11.130.130

Published: 2008

Journal Articles

Cucurbitacin D Upregulates Fetal Hemoglobin Expression in K562 Cells and Human Erythroid Progenitors.

Hongtao Xing, PhD, Siwei Zhang, M.Phil., H. Phillip Koeffler, M.D., Ming Chiu Fung, Ph.D.

Blood (2007) 110 (11): 3833.

https://doi.org/10.1182/blood.V110.11.3833.3833

Published: 2007

Journal Articles

A New Generation of γGlobin Gene Inducers Act on Novel Molecular and Cellular Targets.

Susan Perrine, MD, Marie Trudel, DSc, Serguei A. Castaneda, MD, Rishikesh Mankidy, PhD, Michael S. Boosalis, PhD, Marthe-Sandrine Eiymo, Mwa Mpollo, Gary L. White, PhD, Regine Bohacek, PhD, Douglas V. Faller, PhD

Blood (2006) 108 (11): 1580.

https://doi.org/10.1182/blood.V108.11.1580.1580

Published: 2006

Journal Articles

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

Steven D. Gore, MD, Anchalee Jiemjit, MS, Lewis B. Silverman, MD, Timothy Aucott, Stephen Baylin, MD, Hetty Carraway, MD, Tianna Dauses, BSN, Tamer Fandy, PhD, James Herman, MD, Judith E. Karp, MD, Jonathan D. Licht, MD, Anthony J. Murgo, MD, Rosalie Odchimar-Reissig, BSN, B. Douglas Smith, MD, James A. Zwiebel, MD, Elizabeth Sugar, PhD

Blood (2006) 108 (11): 517.

https://doi.org/10.1182/blood.V108.11.517.517

Published: 2006

Journal Articles

The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.

Derek A. West, BS, David M. Lucas, PhD, Melanie E. Davis, PhD, Michael D. De Lay, BA, Amy J. Johnson, PhD, Sara E. Guster, MS/MBA, Michael A. Freitas, PhD, Mark R. Parthun, PhD, Dasheng Wang, PhD, Samuel K. Kulp, PhD/DVM, Michael R. Grever, MD, Ching-Shih Chen, PhD, John C. Byrd, MD

Blood (2006) 108 (11): 2807.

https://doi.org/10.1182/blood.V108.11.2807.2807

Published: 2006

Journal Articles

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

Jin Sun, PhD, Shujun Liu, PhD, Jianhua Yu, PhD, Min Wei, BS, Charlene Mao, PhD, Haiming Ding, PhD, Jessica Kearney, BS, LeNguyen Huynh, MS, Peter Paschka, MD, Dachun Wang, PhD, Rebecca B. Klisovic, MD, Danilo Perrotti, PhD, Ching-shih Chen, PhD, Williom George Blum, MD, Guido Marcucci, MD

Blood (2006) 108 (11): 1988.

https://doi.org/10.1182/blood.V108.11.1988.1988

Published: 2006

Journal Articles

Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency.

A.M. Almeida, MD, Y. Murakami, PhD, A. Baker, MD, Y. Maeda, PhD, Irene Roberts, PhD, Taroh Kinoshita, PhD, D.M. Layton, MD, A. Karadimitris, PhD

Blood (2006) 108 (11): 487.

https://doi.org/10.1182/blood.V108.11.487.487

Published: 2006

Journal Articles

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2769.

https://doi.org/10.1182/blood.V106.11.2769.2769

Published: 2005

Journal Articles

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Steven D. Gore, MD, Stephen B. Baylin, MD, Tianna Dauses, RN, Michael R. Grever, MD, Anchalee Jiemjit, MS, Jasper Manning, MS, Carole B. Miller, MD, Anthony J. Murgo, MD, James A. Zwiebel, MD, James G. Herman, MD

Blood (2004) 104 (11): 469.

https://doi.org/10.1182/blood.V104.11.469.469

Published: 2004

Journal Articles

Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.

Fei Guo, Ph.D., Celia Sigua, M.S., Purva Bali, M.S., Warren Fiskus, Ph.D., Gautam Sondarva, Ph.D., Srinivas Annavarapu, M.S., Abdelmoughite Mouttaki, B.S., Peter Atadja, Ph.D., Kapil N. Bhalla, M.D.

Blood (2004) 104 (11): 1171.

https://doi.org/10.1182/blood.V104.11.1171.1171

Published: 2004

Journal Articles

Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo

Betty S. Pace, Gary L. White, George J. Dover, Michael S. Boosalis, Douglas V. Faller, Susan P. Perrine

Blood (2002) 100 (13): 4640–4648.

https://doi.org/10.1182/blood-2002-02-0353

Published: 2002

NARROW

The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants

The Impacts of Transcriptional Regulatory Mechanism and Protein Interaction Relationship between RUNX1 and KLF4 on the Biological Functions of t (8;21) Leukemia Cells

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Cucurbitacin D Upregulates Fetal Hemoglobin Expression in K562 Cells and Human Erythroid Progenitors.

A New Generation of γGlobin Gene Inducers Act on Novel Molecular and Cellular Targets.

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency.

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.

Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only